MA38898A1 - Combinaison de facteurs épigénétiques et de composés bispécifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde - Google Patents

Combinaison de facteurs épigénétiques et de composés bispécifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde

Info

Publication number
MA38898A1
MA38898A1 MA38898A MA38898A MA38898A1 MA 38898 A1 MA38898 A1 MA 38898A1 MA 38898 A MA38898 A MA 38898A MA 38898 A MA38898 A MA 38898A MA 38898 A1 MA38898 A1 MA 38898A1
Authority
MA
Morocco
Prior art keywords
myeloid leukemia
treatment
epigenetic
targeting
factor
Prior art date
Application number
MA38898A
Other languages
English (en)
Inventor
Roland B Walter
Marion Subklewe
Christina Krupka
Original Assignee
Amgen Inc
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Amgen Res Munich Gmbh filed Critical Amgen Inc
Publication of MA38898A1 publication Critical patent/MA38898A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition de facteurs épigénétiques et de composés bispécifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde, le facteur épigénétique étant sélectionné parmi les inhibiteurs d'histone désacétylase (hdac), les inhibiteurs d'adn méthyltransférase (dnmt) i, l'hydroxyurée, le facteur de croissance des granulocytes (g-csf), les inhibiteurs d'histone déméthylase et l'atra (acide rétinoïque totalement trans). L'invention concerne donc une composition pharmaceutique contenant un composé ciblant cd33 et au moins un facteur épigénétique, la composition pharmaceutique servant à améliorer et/ou à traiter une leucémie myéloïde, le facteur épigénétique augmentant la sensibilité d'un patient à un composé ciblant cd33. De plus, l'invention concerne l'utilisation d'au moins un facteur épigénétique pour augmenter la sensibilité d'un patient souffrant d'une leucémie myéloïde à un traitement avec un composé ciblant cd33, un procédé de traitement d'une leucémie myéloïde, le procédé comprenant l'administration d'au moins un facteur épigénétique et d'un composé ciblant cd33 à un patient ayant besoin d'un tel traitement et un kit comprenant une composition pharmaceutique de l'invention ou un facteur épigénétique de l'invention et un composé bispécifique ciblant cd33.
MA38898A 2013-09-13 2016-03-09 Combinaison de facteurs épigénétiques et de composés bispécifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde MA38898A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877714P 2013-09-13 2013-09-13
PCT/EP2014/069575 WO2015036583A2 (fr) 2013-09-13 2014-09-15 Combinaison de facteurs épigénétiques et de composés bispécifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde

Publications (1)

Publication Number Publication Date
MA38898A1 true MA38898A1 (fr) 2018-01-31

Family

ID=51690351

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46164A MA46164B1 (fr) 2013-09-13 2014-09-15 Combinaison de facteurs epignetique et de composes bispecifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde
MA38898A MA38898A1 (fr) 2013-09-13 2016-03-09 Combinaison de facteurs épigénétiques et de composés bispécifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA46164A MA46164B1 (fr) 2013-09-13 2014-09-15 Combinaison de facteurs epignetique et de composes bispecifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde

Country Status (28)

Country Link
US (1) US10933132B2 (fr)
EP (1) EP3043794B1 (fr)
JP (1) JP6530409B2 (fr)
KR (1) KR102366470B1 (fr)
CN (2) CN111888474A (fr)
AP (1) AP2016009132A0 (fr)
AR (1) AR097648A1 (fr)
AU (2) AU2014320246B2 (fr)
CA (1) CA2923354C (fr)
CL (1) CL2016000564A1 (fr)
DK (1) DK3043794T3 (fr)
EA (1) EA036476B1 (fr)
HK (1) HK1225975A1 (fr)
HU (1) HUE056867T2 (fr)
IL (1) IL278527B (fr)
JO (1) JO3597B1 (fr)
LT (1) LT3043794T (fr)
MA (2) MA46164B1 (fr)
MX (1) MX2016003197A (fr)
MY (1) MY185611A (fr)
NZ (1) NZ716448A (fr)
PH (1) PH12016500434B1 (fr)
SG (2) SG10201801777YA (fr)
SI (1) SI3043794T1 (fr)
TW (1) TWI688401B (fr)
UA (1) UA123199C2 (fr)
WO (1) WO2015036583A2 (fr)
ZA (1) ZA201600528B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN108289949B (zh) * 2015-05-29 2022-04-12 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
JP6945532B2 (ja) * 2015-12-16 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改善された組換え体作製方法
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
DK3600419T5 (en) * 2017-03-20 2024-05-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
WO2019103531A1 (fr) * 2017-11-24 2019-05-31 충북대학교 산학협력단 Anticorps anti-icam4 et composition pour le diagnostic et le traitement d'une maladie associée à une cellule d'expression d'icam4
KR102090407B1 (ko) * 2017-11-24 2020-03-17 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
WO2019108789A1 (fr) 2017-11-29 2019-06-06 The Trustees Of Columbia University In The City Of New York Polythérapie contre un lymphome
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
AU2019313444A1 (en) * 2018-07-30 2021-02-18 Amgen Inc. Prolonged administration of a bispecific antibody construct binding to CD33 and CD3
WO2020056170A1 (fr) 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Réduction de l'expression de cd33 pour protéger sélectivement des cellules thérapeutiques
CN113045664B (zh) 2019-11-28 2023-05-12 尚健单抗（北京）生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
EP4268895A3 (fr) 2019-12-09 2024-01-10 Chigenovo Co., Ltd. Utilisations de cyp4v2 et rdcvf dans la préparation de médicaments
CN112079934B (zh) 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
WO2021136263A1 (fr) 2020-01-02 2021-07-08 江苏茂行科技有限公司 Cellule effectrice immunitaire modifiée et son procédé de préparation
CN113481165B (zh) * 2020-07-16 2022-06-03 山东博安生物技术股份有限公司 分泌双特异性t细胞衔接子的car-t及治疗实体肿瘤的应用
CN111733174B (zh) 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
TW202222840A (zh) 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
BR112023013790A2 (pt) 2021-01-11 2023-10-03 Starmab Biologics Suzhou Co Ltd Proteína de ligação a antígeno dirigida à alfa-toxina de staphylococcus aureus e aplicação da mesma
KR20230132511A (ko) 2021-01-13 2023-09-15 상하이 후아오타 바이오파마슈티컬 컴퍼니 리미티드 Cd73에 결합하는 단백질 및 이의 용도
CN112630438B (zh) * 2021-03-08 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
KR20230162797A (ko) 2021-03-22 2023-11-28 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 뉴몰리신을 표적으로 하는 항원 결합 단백질 및 이의 용도
EP4299593A1 (fr) 2021-04-02 2024-01-03 Oricell Therapeutics Co., Ltd. Protéine de liaison à l'antigène cldn18.2 et son utilisation
CN113533729A (zh) * 2021-06-15 2021-10-22 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN115612674A (zh) 2021-07-14 2023-01-17 上海荣瑞医药科技有限公司 一种溶瘤病毒及其用途
CN113461821B (zh) * 2021-09-03 2021-12-28 苏州近岸蛋白质科技股份有限公司 抗cd3人源化抗体
CN114908087B (zh) * 2022-05-07 2024-01-23 四川大学华西医院 一种长循环肾靶向细胞外囊泡的构建及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0272253A4 (fr) 1986-03-07 1990-02-05 Massachusetts Inst Technology Procede pour ameliorer la stabilite des glycoproteines.
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0318554B2 (fr) 1987-05-21 2005-01-12 Micromet AG Proteines mutifonctionnelles a cible predeterminee
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993015722A1 (fr) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
WO1999049019A2 (fr) 1998-03-27 1999-09-30 Prolume, Ltd. Luciferases, proteines fluorescentes, acides nucleiques codant pour les luciferases et les proteines fluorescentes, et leur utilisation dans des diagnostics, des criblages a haut rendement et des articles nouveaux
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
EP3461842A1 (fr) 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Domaine de liaison hétérospécifique
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
AR097648A1 (es) 2016-04-06
AP2016009132A0 (en) 2016-04-30
NZ716448A (en) 2022-02-25
PH12016500434A1 (en) 2016-05-16
DK3043794T3 (da) 2021-11-15
SG11201600671QA (en) 2016-02-26
MA46164B1 (fr) 2021-04-30
UA123199C2 (uk) 2021-03-03
LT3043794T (lt) 2021-10-25
CN111888474A (zh) 2020-11-06
CA2923354C (fr) 2022-11-29
MX2016003197A (es) 2016-06-02
TWI688401B (zh) 2020-03-21
TW201605473A (zh) 2016-02-16
SI3043794T1 (sl) 2021-11-30
EP3043794B1 (fr) 2021-09-01
JO3597B1 (ar) 2020-07-05
MA46164A1 (fr) 2020-12-31
EA036476B1 (ru) 2020-11-13
IL278527A (fr) 2020-12-31
MY185611A (en) 2021-05-25
WO2015036583A2 (fr) 2015-03-19
CN105764505A (zh) 2016-07-13
KR20160058120A (ko) 2016-05-24
AU2014320246A1 (en) 2016-02-18
AU2020202641A1 (en) 2020-05-14
WO2015036583A3 (fr) 2015-07-02
ZA201600528B (en) 2021-06-30
JP6530409B2 (ja) 2019-06-12
EP3043794A2 (fr) 2016-07-20
AU2014320246B2 (en) 2020-01-23
HK1225975A1 (zh) 2017-09-22
HUE056867T2 (hu) 2022-03-28
IL278527B (en) 2022-07-01
JP2016536341A (ja) 2016-11-24
SG10201801777YA (en) 2018-04-27
CA2923354A1 (fr) 2015-03-19
CL2016000564A1 (es) 2017-03-24
KR102366470B1 (ko) 2022-02-24
EA201690485A1 (ru) 2016-08-31
PH12016500434B1 (en) 2016-05-16
US10933132B2 (en) 2021-03-02
US20160317657A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
MA38898A1 (fr) Combinaison de facteurs épigénétiques et de composés bispécifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
Iosue et al. Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
TN2014000195A1 (fr) 2-thiopyrimidinones
ATE533489T1 (de) Behandlung von multiplem myelom
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
MA44021A (fr) Composés antitumoraux
RU2014149559A (ru) Селективные ингибиторы недифференцированных клеток
MA37880A1 (fr) Formulation transdermique contenant des inhibiteurs de cox
MA35336B1 (fr) Bloqueurs des canaux sodiques voltage-dependants
MX2014005498A (es) Metodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteina 1 similar a transducina b (tbl1), que inlcuyen la neoplasia mieloproliferativa y la leucemia mieloide cronica.
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
MA52375B2 (fr) Inhibiteurs de cdk8/19
EA202191469A1 (ru) Восстановление посредством антисмысловых олигонуклеотидов abca4 с аберрантным сплайсингом
MA33938B1 (fr) 5-alcynyl-pyrimidines
FR3086542B1 (fr) Utilisation d'un extrait d'agave pour renforcer la fonction barriere de la peau, du cuir chevelu et/ou des muqueuses et moduler le microbiote cutane
FR3068893B1 (fr) Extrait de tulipe
AR104172A1 (es) Terapia de combinación con fgfr / pd-1 para el tratamiento del cáncer
MA55888B1 (fr) Hétéroarylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
EA202192117A1 (ru) Способ лечения множественной миеломы
MA55892B1 (fr) Phénylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
MA57420B1 (fr) Composés anticancéreux